15397-12-3 | 2'-C-Methyladenosine

Packsize	Purity	Availability	Price	Discounted Price
100mg	95%	in stock	$149.00	$104.00
250mg	95%	in stock	$246.00	$172.00
1g	95%	in stock	$483.00	$338.00
5g	95%	in stock	$1,940.00	$1,358.00

Description

• Catalog Number: AD48232
• Chemical Name: 2'-C-Methyladenosine
• CAS Number: 15397-12-3
• Molecular Formula: C11H15N5O4
• Molecular Weight: 281.2679
• MDL Number: MFCD02682944
• SMILES: OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1cnc2c1ncnc2N

Computed Properties

• Complexity: 375
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 2
• XLogP3: -1.3

Literature

• Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.

  Antimicrobial agents and chemotherapy 20140601

• Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.

  Antimicrobial agents and chemotherapy 20140401

• Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.

  Antimicrobial agents and chemotherapy 20130201

• Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.

  Antimicrobial agents and chemotherapy 20130201

• Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.

  Virology 20120720

• Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.

  Bioorganic & medicinal chemistry letters 20120615

• Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

  The Journal of infectious diseases 20120215

• The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.

  Bioorganic & medicinal chemistry 20120101

• Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

  Hepatology (Baltimore, Md.) 20111201

• Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents.

  Bioorganic & medicinal chemistry letters 20111115

• Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.

  Journal of hepatology 20110501

• Synthesis and anti-hepatitis C virus (HCV) activity of 3'-C-substituted-methyl pyrimidine and purine nucleosides.

  Bioorganic & medicinal chemistry 20100701

• Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture.

  PLoS pathogens 20100501

• A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

  Antiviral research 20091101

• Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.

  Antiviral research 20090801

• The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.

  Bioorganic & medicinal chemistry letters 20090801

• N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.

  Journal of medicinal chemistry 20090423

• Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

  Journal of medicinal chemistry 20090108

• Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.

  Journal of medicinal chemistry 20080724

• Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

  Antimicrobial agents and chemotherapy 20080501

• Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.

  Bioorganic & medicinal chemistry 20080301

• Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.

  Bioorganic & medicinal chemistry 20080201

• Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing.

  Antiviral research 20071201

• Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.

  Journal of medicinal chemistry 20070809

• Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.

  Bioorganic & medicinal chemistry 20070801

• Synthesis of 2-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agents.

  Bioorganic & medicinal chemistry letters 20060815

• In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.

  Virology 20060801

• Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.

  Journal of medicinal chemistry 20060420

• Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.

  Bioorganic & medicinal chemistry letters 20060315

• Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

  Antiviral chemistry & chemotherapy 20060101

• Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.

  Journal of medicinal chemistry 20050908

• Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.

  Journal of medicinal chemistry 20050728

• Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

  Antimicrobial agents and chemotherapy 20050501

• Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.

  Journal of medicinal chemistry 20050310

• Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication.

  Bioorganic & medicinal chemistry letters 20050201

• Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.

  Journal of medicinal chemistry 20041007

• Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

  Journal of medicinal chemistry 20040422

• Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.

  The Journal of biological chemistry 20031205

• Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.

  The Journal of biological chemistry 20030404

• Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.

  Journal of medicinal chemistry 20020314

• 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.

  Journal of medicinal chemistry 19980507